Tube choledochoureterostomy: A simple method for bile diversion

A technique of bile diversion by tube choledochoureterostomy has been devised for the purpose of studying the role of bile in the intestinal absorption of drugs. This method was used in six dogs. No technical difficulties or major complications developed, as are inevitable with alternative methods, including external fistula. © 1990 Informa UK Ltd All rights reserved: reproduction in whole or part not permitted

Search for {\eta}'(958)-nucleus bound states by (p,d) reaction at GSI and FAIR

The mass of the {\eta}' meson is theoretically expected to be reduced at finite density, which indicates the existence of {\eta}'-nucleus bound states. To investigate these states, we perform missing-mass spectroscopy for the (p, d) reaction near the {\eta}' production threshold. The overview of the experimental situation is given and the current status is discussed.Comment: 6 pages, 3 figures; talk at II Symposium on applied nuclear physics and innovative technologies, September 24th - 27th, 2014, Jagiellonian University, Krak\'ow Poland; to appear in Acta Physica Polonica

Spectroscopy of η′\eta'-nucleus bound states at GSI and FAIR --- very preliminary results and future prospects ---

The possible existence of \eta'-nucleus bound states has been put forward through theoretical and experimental studies. It is strongly related to the \eta' mass at finite density, which is expected to be reduced because of the interplay between the $U_A(1)$ anomaly and partial restoration of chiral symmetry. The investigation of the C(p,d) reaction at GSI and FAIR, as well as an overview of the experimental program at GSI and future plans at FAIR are discussed.Comment: 7 pages, 3 figures; talk at the International Conference on Exotic Atoms and Related Topics (EXA2014), Vienna, Austria, 15-19 September 2014. in Hyperfine Interactions (2015

Self-Similar Bootstrap of Divergent Series

A method is developed for calculating effective sums of divergent series. This approach is a variant of the self-similar approximation theory. The novelty here is in using an algebraic transformation with a power providing the maximal stability of the self-similar renormalization procedure. The latter is to be repeated as many times as it is necessary in order to convert into closed self-similar expressions all sums from the series considered. This multiple and complete renormalization is called self-similar bootstrap. The method is illustrated by several examples from statistical physics.Comment: 1 file, 22 pages, RevTe

Demographic, clinical and antibody characteristics of patients with digital ulcers in systemic sclerosis: data from the DUO Registry

OBJECTIVES: The Digital Ulcers Outcome (DUO) Registry was designed to describe the clinical and antibody characteristics, disease course and outcomes of patients with digital ulcers associated with systemic sclerosis (SSc). METHODS: The DUO Registry is a European, prospective, multicentre, observational, registry of SSc patients with ongoing digital ulcer disease, irrespective of treatment regimen. Data collected included demographics, SSc duration, SSc subset, internal organ manifestations, autoantibodies, previous and ongoing interventions and complications related to digital ulcers. RESULTS: Up to 19 November 2010 a total of 2439 patients had enrolled into the registry. Most were classified as either limited cutaneous SSc (lcSSc; 52.2%) or diffuse cutaneous SSc (dcSSc; 36.9%). Digital ulcers developed earlier in patients with dcSSc compared with lcSSc. Almost all patients (95.7%) tested positive for antinuclear antibodies, 45.2% for anti-scleroderma-70 and 43.6% for anticentromere antibodies (ACA). The first digital ulcer in the anti-scleroderma-70-positive patient cohort occurred approximately 5 years earlier than the ACA-positive patient group. CONCLUSIONS: This study provides data from a large cohort of SSc patients with a history of digital ulcers. The early occurrence and high frequency of digital ulcer complications are especially seen in patients with dcSSc and/or anti-scleroderma-70 antibodies